Fibre-optic Guided Tracheal Intubation Through SADs

Fibre-optic Guided Tracheal Intubation Through Supraglottic Airway Devices - a Randomised Comparison Between I-gel and the LMA ProtectorTM

The study aims to establish which of the two second generation Supraglottic Airway Devices, the I-gel or the the laryngeal ask airway (LMA) Protector, is best suited to be used as a conduit to fibreoptic bronchoscope assisted tracheal intubation. The primary outcome of this will be the time to complete the tracheal intubation.

Study Overview

Detailed Description

Tracheal intubation through a supraglottic airway device (SAD) is a well-established technique in the management of patients with a difficult airway. The technique can be used in patients in whom difficult intubation is expected, or in situations when tracheal intubation using another method was not possible. It is now recommended that tracheal intubation through the SAD should be performed using a fibreoptic scope (a camera device) to minimise the risk of trauma to the airway, and that second generation SADs are used to minimise the risk of aspiration of gastric contents.

There are two second generation SADs currently available which allow tracheal intubation: the I-gel and the LMA protector.

The I-gel is a second generation supraglottic airway device widely used in anaesthesia and resuscitation. Fibreoptic intubation through the I-gel has been evaluated in a recent prospective study (1), with the first attempt success rate of 91.4%. In another study (2) of patients with predicted difficult airway, the success rate of the procedure at first attempt was 96%.

LMA Protector is a recently introduced, improved version the LMA supreme - another second generation SAD. LMA supreme has been used in clinical practice for more than 10 years, however, tracheal intubation through the device was extremely difficult because of the small size of the breathing channel. The LMA Protector, has a larger breathing channel allowing the passage of an endotracheal tube. Compared to the I-gel, is has also got a larger gastric drainage tube. This allows easy suction in the event of regurgitation. Therefore, it appears to be superior to the I-gel in preventing the aspiration. But there are no studies comparing the ease of intubation through I-gel and LMA Protector

The aim of this study is to compare the ease of performing the fibreoptic guided tracheal intubation through these two devices. Our hypothesis is that intubation through the I-gel is easier and quicker.

Study Type

Interventional

Enrollment (Actual)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oxford, United Kingdom, OX3 7LE
        • Oxford University Hospitals
    • West Midlands
      • Coventry, West Midlands, United Kingdom, CV2 2DX
        • University Hospitals Coventry & Warwickshire NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

• All patients aged above 18, presenting for elective surgical procedure, where a supraglottic airway device can be used and left in place throughout the duration of surgery and requiring tracheal intubation

Exclusion Criteria:

  • Patients who are do not wish to take part
  • Patients with class II obesity (BMI >40)
  • Patients below 18 years of age
  • American Society of Anaesthesiologists (ASA 3, 4 and 5)
  • Patients with mouth opening of less than 3 cm
  • Patients deemed to require awake intubation
  • Surgery involving head and neck region
  • Surgery requiring prone position

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: I-gel
Fibreoptic guided tracheal intubation through I-gel
Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
ACTIVE_COMPARATOR: LMA Protector
Fibreoptic guided tracheal intubation through Protector
Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Intubation Time to Perform Fibreoptic Intubation
Time Frame: less than 3 minutes
Time form insertion of bronchoscope through the supraglottic airway device to obtaining the capnography trace
less than 3 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SAD Insertion Time
Time Frame: less than 1 minute
Time taken to insert the supra-glottic airway device measured from insertion into the mouth until the capnography trace is obtained
less than 1 minute
Number of Attempts at the SAD Placement
Time Frame: less than 2 minutes
Number of attempts taken to successfully place the supraglottic airway device in the oropharynx
less than 2 minutes
Number of Participants With Ease of Placement of the SAD
Time Frame: less than 2 minutes

The ease of placement of the SAD assessed by the investigator on a four point scale:

  1. - Easy
  2. - Moderate Difficulty 3- Severe Difficulty

4 - Failure

less than 2 minutes
Number of Participants With First and Second Attempt at Tracheal Intubation
Time Frame: less than 3 minutes
Number of attempts at tracheal intubation. A new attempt is defined as re-insertion of the fibreoptic bronchoscope through the SAD.
less than 3 minutes
Number of Participants With Quality of the View of the Vocal Cords Seen Through the SAD
Time Frame: less than 3 minutes
The quality of the view of the vocal cords seen through the SAD. It will be assessed, according to the previously published system, as: grade I - full view of the vocal cord, II - partial view of the vocal cords including arytenoids, III - epiglottis only, IV - other (SAD cuff, pharynx, others)
less than 3 minutes
Time to Carinal View
Time Frame: less than 1 minute
The time from insertion of fibreoptic scope into the lumen of the SAD to the visualization of the carina.
less than 1 minute
Number of Participants With Type of Airway Maneuvers Performed During Tracheal Intubation,
Time Frame: less than 3 minutes
The number of tube rotations performed during tracheal intubation
less than 3 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cyprian Mendonca, Prof., University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 24, 2017

Primary Completion (ACTUAL)

March 26, 2018

Study Completion (ACTUAL)

March 26, 2018

Study Registration Dates

First Submitted

April 13, 2017

First Submitted That Met QC Criteria

April 13, 2017

First Posted (ACTUAL)

April 18, 2017

Study Record Updates

Last Update Posted (ACTUAL)

April 9, 2020

Last Update Submitted That Met QC Criteria

March 27, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • UHCoventryNHS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Airway Management

Clinical Trials on I-gel

3
Subscribe